Comparative Efficiency of Sulfonylurea and/or Dipeptidyl Peptidase-4 inhibitor in Basal-Supported Oral Therapy in Japanese Patients with Type 2 Diabetes (JDDM39)
Koichi Hirao2, Shin-ichiro Sirabe2, Hajime Maeda2, Ritsuko Yamamoto2, Atushi Kumakura3, Namiko Samoto2, Atsunori Kashiwagi4, Japan Diabetes Clinical Data Management Study Group
Corresponding Author
Keiko Arai, M.D., Ph.D. Arai Clinic, 1-19, Moegino, Aoba-ku, Yokohama 227-0044, Japan. Tel: +81-45-532-8820, Fax: +81-45-532-8821; E-mail: arai-cl@n04.itscom.net
Citation
Arai, K., et al. Comparative Efficiency of Sulfonylurea and/or Dipeptidyl Peptidase-4 Inhibitor in Basal-Supported Oral Therapy in Japanese Patients with Type 2 Diabetes (JDDM 39). (2015) J Diab Obes 2(2): 79- 84.
Copy rights
©2015 Arai, K. This is an Open access article distributed under the terms of Creative Commons Attribution 4.0 International License.
Keywords
Abstract
Basal-supported Oral Therapy (BOT), comprising treatment with oral antidiabetic drugs and once-daily injections of a long-acting insulin analog, is a convenient regimen. However, it sometimes fails to achieve satisfactory glycemic control because of uncontrolled hyperglycemia in the postprandial period. The aim of the present retrospective cohort study was to assess the efficiency of a sulfonylurea (SU) and/or a dipeptidyl peptidase-4 inhibitor (DPP-4i) on glycemic control in Japanese patients with type 2 diabetes mellitus (T2DM) who were receiving BOT. The 243 T2DM patients who started long-acting insulin added onto an SU and/or DPP-4i, with or without metformin, were followed-up for 6 months. Mean HbA1c levels in the SU, DPP-4i, and SU + DPP-4i groups decreased steadily from baseline by approximately 1% over the 6-month followed-up period. After 6 months, 57.4%, 51.6%, and 62.2% of patients in the SU, DPP-4i, and SU + DPP-4i groups, respectively, had continued on the same therapeutic regimen, and 15.2%, 18.5%, and 16.5% of patients, respectively, had achieved HbA1c levels <7.0%. The efficiency of BOT with SU, DPP-4i, and SU + DPP-4i was limited, but some patients (i.e. those with a lower body mass index and HbA1c) may benefit from these BOT regimens.
